XXII
22nd Century Group, Inc. [XXII] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
XXII Stock Summary
In the News
Why Is 22nd Century (XXII) Stock Down 33% Today?
22nd Century (NASDAQ: XXII ) stock is falling on Monday as the tobacco products company is in danger of being delisted from the Nasdaq Exchange . The tobacco company was sent a delisting notice from the Nasdaq Listing Qualifications Department last week.
Why Is 22nd Century Group (XXII) Stock Up 100% Today?
Shares of tobacco specialist 22nd Century Group (NASDAQ: XXII ) are up today after the company announced a “significant” new contract manufacturing agreement. The deal centers on the production of branded conventional cigarette products.
22nd Century Group, Inc. (XXII) Q4 2023 Earnings Call Transcript
22nd Century Group, Inc. (XXII) Q4 2023 Earnings Call Transcript
22nd Century Group to Announce Fourth Quarter 2023 Results on March 28, 2024
Mocksville, North Carolina--(Newsfile Corp. - March 15, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco company focused on tobacco harm reduction to improve smoker health and wellness, will host a live webcast on Thursday, March 28, 2024, at 8:00 AM ET to discuss its 2023 fourth quarter results, which are to be reported in a press release at 6:00 AM ET the same day. During the webcast, Larry Firestone, chairman and chief executive officer, and Hugh Kinsman, chief financial officer, will review financial results and discuss progress made in the recent months.
3 Tobacco Stocks Grabbing Attention on Solid Industry Trends
The Zacks Tobacco industry companies have been benefiting from their pricing power and strength in smoke-free products amid an inflationary landscape. These upsides keep Philip Morris (PM), Altria Group (MO) and 22nd Century Group (XXII) well-placed.
22nd Century Group to Present at the Emerging Growth Conference on February 8, 2024
Mocksville, North Carolina--(Newsfile Corp. - February 6, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII) (the "Company" or "22nd Century"), a biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced that the Company will present at the Emerging Growth Conference on February 8, 2024. Larry Firestone, Chairman and Chief Executive Officer, will present as part of an interactive Q&A session with the conference host at 10:50 am Eastern Time.
22nd Century (XXII) Expands VLN Cigarettes to 1,200 Drug Stores
22nd Century Group's (XXII) VLN cigarettes represent a remarkable breakthrough as the first and only combustible cigarettes that the FDA has authorized as Modified Risk Tobacco Products.
22nd Century (XXII) Begins Strategic Review of Tobacco Assets
22nd Century (XXII) is embarking on a strategic journey to unlock the full potential of its tobacco assets. This reflects the company's commitment to delivering long-term value to its shareholders.
All You Need to Know About 22nd Century (XXII) Rating Upgrade to Buy
22nd Century (XXII) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The 3 Most Undervalued Penny Stocks to Buy Now: August 2023
Penny stocks are often defined as stocks trading under $5 per share, those with a very low price per share or market capitalization, and are generally higher-risk. Now, despite many such stocks certainly carrying a relatively high risk profile, this often is somewhat offset by higher potential returns.
XXII Financial details
XXII Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 49.25 | 48.6 | 47.55 | 1.16K | 24.88 | |
| Net income per share | -46.13 | -34.08 | -50.1 | -1.12K | -108.75 | |
| Operating cash flow per share | -27.81 | -27.01 | -35.09 | -965.43 | -42.48 | |
| Free cash flow per share | -29.89 | -27.91 | -36.74 | -1.05K | -46.82 | |
| Cash per share | 74.28 | 38.63 | 74.88 | 396.02 | 1.59 | |
| Book value per share | 118.3 | 76.26 | 101.52 | 1.79K | -6.5 | |
| Tangible book value per share | 102.11 | 62.07 | 89.35 | 858.04 | -11.07 | |
| Share holders equity per share | 118.3 | 76.26 | 101.52 | 1.79K | -6.5 | |
| Interest debt per share | 2.92 | 1.48 | 3.68 | 132.25 | 18.58 | |
| Market cap | 138.4M | 305.24M | 482.44M | 11.83M | 3.86M | |
| Enterprise value | 139.39M | 304.99M | 483.44M | 15.54M | 18.18M | |
| P/E ratio | -5.72 | -15.49 | -14.79 | -0.2 | -0.03 | |
| Price to sales ratio | 5.36 | 10.86 | 15.59 | 0.19 | 0.12 | |
| POCF ratio | -9.49 | -19.54 | -21.12 | -0.23 | -0.07 | |
| PFCF ratio | -8.83 | -18.91 | -20.18 | -0.21 | -0.06 | |
| P/B Ratio | 2.23 | 6.92 | 7.3 | 0.12 | -0.46 | |
| PTB ratio | 2.23 | 6.92 | 7.3 | 0.12 | -0.46 | |
| EV to sales | 5.4 | 10.85 | 15.62 | 0.25 | 0.56 | |
| Enterprise value over EBITDA | -6.24 | -18.87 | -19.96 | -0.26 | -0.49 | |
| EV to operating cash flow | -9.56 | -19.52 | -21.17 | -0.3 | -0.33 | |
| EV to free cash flow | -8.89 | -18.89 | -20.22 | -0.28 | -0.3 | |
| Earnings yield | -0.17 | -0.06 | -0.07 | -5.06 | -36.49 | |
| Free cash flow yield | -0.11 | -0.05 | -0.05 | -4.75 | -15.71 | |
| Debt to equity | 0.02 | 0.02 | 0.04 | 0.07 | -1.75 | |
| Debt to assets | 0.02 | 0.02 | 0.03 | 0.06 | 0.53 | |
| Net debt to EBITDA | -0.04 | 0.02 | -0.04 | -0.06 | -0.39 | |
| Current ratio | 7.39 | 3.86 | 6.45 | 3.43 | 0.65 | |
| Interest coverage | -397.72 | -263.99 | -488.52 | -161.77 | -4.48 | |
| Income quality | 0.55 | 0.79 | 0.7 | 0.86 | 1.01 | |
| Dividend Yield | 0 | 0 | 0 | 0.01 | 2.54 | |
| Payout ratio | 0 | 0 | -0.01 | 0 | -0.07 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0.52 | 0.99 | |
| Research and developement to revenue | 0.31 | 0.15 | 0.11 | 0.11 | 0.06 | |
| Intangibles to total assets | 0.12 | 0.16 | 0.1 | 0.44 | 0.22 | |
| Capex to operating cash flow | 0.07 | 0.03 | 0.05 | 0.09 | 0.1 | |
| Capex to revenue | -0.04 | -0.02 | -0.03 | -0.07 | -0.17 | |
| Capex to depreciation | -0.77 | -0.34 | -0.7 | -1.23 | -1.16 | |
| Stock based compensation to revenue | 0.14 | 0.06 | 0.13 | 0.09 | 0.08 | |
| Graham number | 350.41 | 241.82 | 338.29 | 6.71K | 126.09 | |
| ROIC | -0.32 | -0.42 | -0.4 | -0.54 | -5.28 | |
| Return on tangible assets | -0.4 | -0.45 | -0.48 | -0.93 | -6.52 | |
| Graham Net | 64.53 | 30.07 | 62.59 | 219.76 | -20.17 | |
| Working capital | 36.96M | 21M | 45.96M | 31.59M | -8.76M | |
| Tangible asset value | 53.56M | 35.9M | 58.16M | 45.96M | -14.33M | |
| Net current asset value | 35.84M | 20.76M | 44.51M | 25.93M | -19.64M | |
| Invested capital | 0.02 | 0.02 | 0.04 | 0.07 | -1.75 | |
| Average receivables | 869.08K | 1.51M | 1.37M | 3.11M | 6.54M | |
| Average payables | 2.29M | 1.56M | 1.64M | 3.17M | 4.31M | |
| Average inventory | 2.66M | 2.15M | 2.46M | 6.44M | 7.18M | |
| Days sales outstanding | 12.25 | 28.03 | 6.9 | 33.15 | 84.31 | |
| Days payables outstanding | 28.24 | 15.27 | 27.46 | 24.97 | 39.05 | |
| Days of inventory on hand | 32.04 | 27.83 | 36.41 | 59.95 | 38.18 | |
| Receivables turnover | 29.8 | 13.02 | 52.9 | 11.01 | 4.33 | |
| Payables turnover | 12.92 | 23.9 | 13.29 | 14.62 | 9.35 | |
| Inventory turnover | 11.39 | 13.11 | 10.02 | 6.09 | 9.56 | |
| ROE | -0.39 | -0.45 | -0.49 | -0.62 | 16.74 | |
| Capex per share | -2.08 | -0.9 | -1.65 | -82.68 | -4.34 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 21.41 | 24.43 | 25.16 | 6.33 | 3.52 | |
| Net income per share | -29.3 | -18.92 | -22.06 | -58.51 | -14.02 | |
| Operating cash flow per share | -21.25 | -19.46 | -21.3 | -10.34 | -2.3 | |
| Free cash flow per share | -22.96 | -21.72 | -22.51 | -11.33 | -2.89 | |
| Cash per share | 23.65 | 18.05 | 4.76 | 2.29 | 0.98 | |
| Book value per share | 106.99 | 90.49 | 77.95 | 11.1 | -4.02 | |
| Tangible book value per share | 51.24 | 33.16 | 19.01 | 5.55 | -6.85 | |
| Share holders equity per share | 106.99 | 90.49 | 77.95 | 11.1 | -4.02 | |
| Interest debt per share | 7.64 | 25.33 | 29.91 | 20.74 | 10.1 | |
| Market cap | 198.08M | 165.86M | 85.49M | 19.44M | 6.23M | |
| Enterprise value | 201.79M | 177.25M | 107.71M | 43.67M | 20.55M | |
| P/E ratio | -1.88 | -2.44 | -1.04 | -0.07 | -0.05 | |
| Price to sales ratio | 10.31 | 7.55 | 3.65 | 2.47 | 0.85 | |
| POCF ratio | -10.39 | -9.48 | -4.31 | -1.51 | -1.3 | |
| PFCF ratio | -9.62 | -8.49 | -4.08 | -1.38 | -1.03 | |
| P/B Ratio | 2.06 | 2.04 | 1.18 | 1.41 | -0.74 | |
| PTB ratio | 2.06 | 2.04 | 1.18 | 1.41 | -0.74 | |
| EV to sales | 10.51 | 8.07 | 4.6 | 5.55 | 2.79 | |
| Enterprise value over EBITDA | -8.48 | -9.98 | -5.59 | -0.91 | -0.65 | |
| EV to operating cash flow | -10.58 | -10.13 | -5.43 | -3.4 | -4.28 | |
| EV to free cash flow | -9.8 | -9.08 | -5.14 | -3.1 | -3.41 | |
| Earnings yield | -0.13 | -0.1 | -0.24 | -3.74 | -4.71 | |
| Free cash flow yield | -0.1 | -0.12 | -0.25 | -0.72 | -0.97 | |
| Debt to equity | 0.07 | 0.27 | 0.37 | 1.96 | -1.75 | |
| Debt to assets | 0.06 | 0.18 | 0.21 | 0.42 | 0.53 | |
| Net debt to EBITDA | -0.16 | -0.64 | -1.15 | -0.5 | -0.45 | |
| Current ratio | 3.43 | 2.44 | 1.47 | 1.02 | 0.65 | |
| Interest coverage | -188.28 | -42.33 | -16.22 | 36.89 | -4.99 | |
| Income quality | 0.73 | 0.96 | 0.97 | 0.18 | 0.22 | |
| Dividend Yield | 0 | 0.03 | 0.09 | 0 | 0 | |
| Payout ratio | 0 | -0.33 | -0.36 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0.63 | 1.46 | -1.19 | |
| Research and developement to revenue | 0.11 | 0.07 | 0.08 | 0.2 | 0.05 | |
| Intangibles to total assets | 0.44 | 0.42 | 0.44 | 0.11 | 0.22 | |
| Capex to operating cash flow | 0.08 | 0.12 | 0.06 | 0.1 | 0.26 | |
| Capex to revenue | -0.08 | -0.09 | -0.05 | -0.16 | -0.17 | |
| Capex to depreciation | -1.43 | -1.72 | -0.78 | -0.75 | -2.71 | |
| Stock based compensation to revenue | 0.05 | 0.05 | 0.06 | 0.07 | -0.08 | |
| Graham number | 265.58 | 196.25 | 196.68 | 120.87 | 35.61 | |
| ROIC | -0.24 | -0.15 | -0.18 | -0.98 | -4.04 | |
| Return on tangible assets | -0.41 | -0.23 | -0.29 | -1.27 | -1.36 | |
| Graham Net | 13.12 | -16.06 | -36.77 | -27.92 | -12.48 | |
| Working capital | 31.59M | 24.27M | 11.77M | 856K | -8.76M | |
| Tangible asset value | 45.96M | 29.81M | 17.71M | 6.9M | -14.33M | |
| Net current asset value | 25.93M | -1.64M | -15.51M | -9.79M | -19.64M | |
| Invested capital | 0.07 | 0.27 | 0.37 | 1.96 | -1.75 | |
| Average receivables | 5.3M | 7.39M | 8.93M | 7.61M | 6.97M | |
| Average payables | 4.98M | 4.39M | 5.53M | 6.73M | 5.73M | |
| Average inventory | 11.14M | 10.27M | 12.42M | 15.14M | 10.15M | |
| Days sales outstanding | 26.43 | 37.42 | 33.56 | 74.24 | 91 | |
| Days payables outstanding | 18.9 | 17.9 | 22.52 | 27.01 | 26.14 | |
| Days of inventory on hand | 45.37 | 40.95 | 50 | 61.51 | 25.56 | |
| Receivables turnover | 3.4 | 2.41 | 2.68 | 1.21 | 0.99 | |
| Payables turnover | 4.76 | 5.03 | 4 | 3.33 | 3.44 | |
| Inventory turnover | 1.98 | 2.2 | 1.8 | 1.46 | 3.52 | |
| ROE | -0.27 | -0.21 | -0.28 | -5.27 | 3.49 | |
| Capex per share | -1.71 | -2.25 | -1.21 | -0.99 | -0.59 |
XXII Frequently Asked Questions
What is 22nd Century Group, Inc. stock symbol ?
22nd Century Group, Inc. is a US stock , located in Buffalo of Ny and trading under the symbol XXII
What is 22nd Century Group, Inc. stock quote today ?
22nd Century Group, Inc. stock price is $1.61 today.
Is 22nd Century Group, Inc. stock public?
Yes, 22nd Century Group, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.45M
- Market Capitalization 5.85M
- Employee 64
- CEO Mr. Lawrence D. Firestone
- Headquarters Buffalo,NY,US
- IPO Date 2011-01-26
-
Website
https://www.xxiicentury.com 
22nd Century Group, Inc., an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries. It develops very low nicotine content tobacco and cigarette products under the VLN King and VLN Menthol King names; and SPECTRUM research cigarettes for use in independent clinical studies. The company has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Buffalo, New York.
